Mitochondrial bioenergetics and drug-induced toxicity in a panel of mouse embryonic fibroblasts with mitochondrial DNA single nucleotide polymorphisms

Toxicology and Applied Pharmacology

Volumn 264, Issue 2, 2012, Pages 167-181

  Pereira, Claudia V ^a   Oliveira, Paulo J ^a   Will, Yvonne ^b   Nadanaciva, Sashi ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b PFIZER INC   (United States)

Author keywords

Bioenergetics; Drug induced toxicity; Mitochondria; MtDNA; Single nucleotide polymorphisms

Indexed keywords

ADENOSINE TRIPHOSPHATE; FLUTAMIDE; GALACTOSE; GLUCOSE; IMIPRAMINE; KETOCONAZOLE; MITOCHONDRIAL DNA; NEFAZODONE; ROTENONE; TAMOXIFEN; TOLCAPONE; TROGLITAZONE;

ANIMAL CELL; ARTICLE; BIOENERGY; C57BL 6J MOUSE STRAIN; CELL GROWTH; CZECHII EIJ MOUSE STRAIN; EMBRYO; EMBRYONIC FIBROBLAST; FIBROBLAST; MITOCHONDRION; MOLF EIJ MOUSE STRAIN; MOUSE; MOUSE STRAIN; NONHUMAN; PERA EIJ MOUSE STRAIN; SINGLE NUCLEOTIDE POLYMORPHISM; STRAIN DIFFERENCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CITRATE (SI)-SYNTHASE; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX IV; EMBRYO, MAMMALIAN; ENERGY METABOLISM; FIBROBLASTS; MICE; MICE, INBRED C57BL; MITOCHONDRIA; OXYGEN CONSUMPTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS, INBRED STRAINS; ROTENONE; SPECIES SPECIFICITY; UNCOUPLING AGENTS;

ANIMALIA;

EID: 84866878955     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.07.030     Document Type: Article

References (42)

1. Abe Y., et al. Bioenergetic characterization of mouse podocytes. Am. J. Physiol. Cell Physiol. 2010, 299:C464-C476.
2. Aliev G., et al. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases. Recent Pat. Cardiovasc. Drug Discov. 2011, 6:222-241.
3. Battersby B.J., et al. Nuclear genetic control of mitochondrial DNA segregation. Nat. Genet. 2003, 33:183-186.
4. Boelsterli U.A., Lim P.L. Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity?. Toxicol. Appl. Pharmacol. 2007, 220:92-107.
5. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
6. Czarnecka A.M., Bartnik E. The role of the mitochondrial genome in ageing and carcinogenesis. J. Aging Res. 2011, 2011:136435.
7. Daly A.K. Pharmacogenetics and human genetic polymorphisms. Biochem. J. 2010, 429:435-449.
8. Deng X., et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 2006, 319:1191-1199.
9. DiMauro S., Schon E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 2003, 348:2656-2668.
10. Dykens J.A., et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 2008, 103:335-345.
11. Feng J.Y., et al. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J. Biol. Chem. 2001, 276:23832-23837.
12. Frazer K.A., et al. Segmental phylogenetic relationships of inbred mouse strains revealed by fine-scale analysis of sequence variation across 4.6 mb of mouse genome. Genome Res. 2004, 14:1493-1500.
13. Funk C., et al. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 2001, 59:627-635.
14. Goios A., et al. mtDNA phylogeny and evolution of laboratory mouse strains. Genome Res. 2007, 17:293-298.
15. Gomez-Duran A., et al. Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups. Hum. Mol. Genet. 2010, 19:3343-3353.
16. Guo Y., et al. In silico pharmacogenetics of warfarin metabolism. Nat. Biotechnol. 2006, 24:531-536.
17. Haasio K., et al. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. 2002, 453:21-26.
18. Harrill A.H., et al. Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel. Toxicol. Sci. 2009, 110:235-243.
19. Hill B.G., et al. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. Biochem. J. 2009, 424:99-107.
20. Holt M.P., Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006, 8:E48-E54.
21. http://cgd.jax.org/cgdsnpdb/.
22. Janssen A.J., et al. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. Clin. Chem. 2007, 53:729-734.
23. Kostrubsky S.E., et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 2006, 90:451-459.
24. Kuroda Y., Saito M. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis. Toxicol. In Vitro 2010, 24:661-668.
25. Lee Y.H., et al. Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. Toxicol. Appl. Pharmacol. 2008, 231:43-51.
26. Marroquin L.D., et al. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 2007, 97:539-547.
27. Martinez S.M., et al. Evaluation of an in vitro toxicogenetic mouse model for hepatotoxicity. Toxicol. Appl. Pharmacol. 2010, 249:208-216.
28. Michikawa Y., et al. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 1999, 286:774-779.
29. Nioi P., Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem. Biophys. Res. Commun. 2007, 362:816-821.
30. Oliveira P.J., Wallace K.B. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology 2006, 220:160-168.
31. O'Shea S.H., et al. In vitro screening for population variability in chemical toxicity. Toxicol. Sci. 2011, 119:398-407.
32. Pelicano H., et al. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
33. Ratkevicius A., et al. H55N polymorphism as a likely cause of variation in citrate synthase activity of mouse skeletal muscle. Physiol. Genomics 2010, 42A:96-102.
34. Rodriguez R.J., Acosta D. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1995, 96:83-92.
35. Rodriguez R.J., Acosta D. Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. J. Biochem. Toxicol. 1996, 11:127-131.
36. Rodriguez R.J., Buckholz C.J. Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding. Xenobiotica 2003, 33:429-441.
37. Svenson K.L., et al. Invited review: identifying new mouse models of cardiovascular disease: a review of high-throughput screens of mutagenized and inbred strains. J. Appl. Physiol. 2003, 94:1650-1659. (discussion 1673).
38. Szatkiewicz J.P., et al. An imputed genotype resource for the laboratory mouse. Mamm. Genome 2008, 19:199-208.
39. Wallace D.C. Mitochondrial DNA mutations in disease and aging. Environ. Mol. Mutagen. 2010, 51:440-450.
40. Wallace D.C., Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion 2010, 10:12-31.
41. http://www.simbiot.net.
42. Yadava N., Nicholls D.G. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J. Neurosci. 2007, 27:7310-7317.